Mechanisms of aflatoxin carcinogenesis

Annual Review of Pharmacology and Toxicology

Volumn 34, Issue , 1994, Pages 135-172

  Eaton, David L ^a   Gallagher, Evan P ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; AFLATOXIN B1; AFLATOXIN B1 8,9 EPOXIDE; ANTIOXIDANT; CYTOCHROME P450 ISOENZYME; FURAFYLLINE; GLUTATHIONE TRANSFERASE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

BIOTRANSFORMATION; CHEMICAL CARCINOGENESIS; DETOXIFICATION; DNA BINDING; GENOTOXICITY; HEPATITIS B VIRUS; HUMAN; LIVER CANCER; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0028174980     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pa.34.040194.001031     Document Type: Review

References (66)

1. Hall AJ, Wild CP. 1994. Epidemiology of aflatoxin-related disease. In The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance, ed. DL Eaton, JD Groopman, pp. 233-58. New York: Academic
2. Robens JF, Richard JL. 1992. Aflatoxins in animal and human health. Rev. Environ. Contam. Toxicol. 127: 69-94
3. Krishnamachari K, Bhat R, Nagarajan V, Tilac T. 1975. Hepatitis due to aflatoxicosis. Lancet 1:1061-63
4. Denning DW. 1987. Aflatoxin and human disease. Adverse Drug React. Acute Poison Rev. 4:175-209
5. Pier AC, McLoughlin ME. 1985. Mycotoxic suppression of immunity. In Trichothecenes and Other Mycotoxins, ed. J Lacey, pp. 507-19. Chichster: Wiley
6. Busby WF, Wogan GN. 1984. Aflatoxins. Chem. Carcinogen. 2:945-1136
7. Wogan G. 1973. Aflatoxin carcinogenesis. In Methods in Cancer Research, ed. H Busch, pp. 309-44. New York/ London: Academic
8. Roebuck BD, Maxuitenko YY. 1994. Biochemical mechanisms and biological implications of the toxicity of aflatoxins as related to aflatoxin carcinogenesis. See Ref. 1, pp. 27-44
9. Groopman JD, Cain LG, Kensler T. 1988. Aflatoxin exposure in human populations: measurements and relationship to cancer. CRC Crit. Rev. Toxicol. 19:113-43
10. Bruce RD. 1990. Risk Assessment of aflatoxins II. Implications of human epidemiology data. Risk Anal. 10:561-69
11. Groopman JD. 1994. Molecular dosimetry methods for assessing human aflatoxin exposure. See Ref. 1, pp. 259-80
12. Stoloff L. 1989. Aflatoxin is not a probable human carcinogen: the pub-lished evidence is sufficient. Regul. Toxicol. Pharmacol. 10:272-83
13. International Agency for Research on Cancer (IARC). 1993. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some Naturally Occurring Substances: Food Items and Constituents, Heterocyclic Aromatic Amines and Mycotoxins. 56:362
14. Halver JE. 1969. Aflatoxicosis and trout hepatoma. In Aflatoxin: Scientific Background, Control and Implications, ed. LA Goldblatt, pp. 265-306. New York: Academic
15. 1 carcinogenesis in the rat. Cancer Res. 27:2730
16. 1 in rats. Food Cosmet. Toxicol. 12:681-85
17. Gold L, Slone TH, Bernstein L. 1984. Summary of carcinogenic potency and positivity for 492 rodent carcinogens in the carcinogenic potency database. Environ. Health Perspect. 79:259-72
18. 1, a hepatocarcinogen in the infant mouse. Cancer Res. 32: 2289-91
19. Hendricks JD. 1994. Carcinogenicity of aflatoxins in nonmammalian organisms. See Ref. 1, pp. 103-36
20. 1. Pharmacol. Ther. 34:321-34
21. Groopman JD, Donahue KF. 1988. Special Report: aflatoxin, a human carcinogen: determination in foods and biological samples by monoclonal antibody affinity chromatography. J. Assoc. Off. Anal. Chem. 71:861-67
22. Groopman JD, Jiaqi Z, Donahue PR, Pikul A, Zhang L, et al. 1992. Mo-lecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China. Cancer Res. 52:45-52
23. 7 -guanine and other aflatoxin metabolites by multiple monoclonal antibody affinity chromatography and HPLC. Cancer Res. 52: 267-74
24. 7-guanine in human urine obtained in the Gambia, West Africa. Cancer Epidemiol. Biomarkers Prev. 1:221-28
25. 1 in human urine. Cancer Res. 47:1848-52
26. Wild CP, Hudson G, Sabbioni G, Wogan GN, Whittle H, et al. 1992. Correlation of dietary intake of aflatoxins with the level of albumin bound aflatoxin in peripheral blood in the Gambia. Cancer Epidemiolog. Biomarkers Prev. 1:229-34
27. Peers F, Bosch X, Kaldor J, Linsell A, Pluijmen M. 1987. Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. Int. J. Cancer 39:545-53
28. Ross RK, Yuan J-M, Yu MC, Wogan GN, Qian G-S, et al. 1992. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339:9343-46
29. 2 to rat liver DNA and ribosomal RNA in vivo. Cancer Res. 37:172-81
30. 1 the ultimate carcinogenic species. J. Am. Chem. Soc. 110:7929-31
31. 1: a new metabolite. Chem. Res. Toxicol. 5:333-35
32. 1 in vivo in rats. Carcinogenesis 8:819-24
33. 1 in vitro by rat liver microsomes. FEBS Lett. 101:382-86
34. 1 carcinogenesis: comparative kinetics of microsomal biotransformation. Cancer Res. 50:615-20
35. Monroe DH, Eaton DL. 1987. Comparative effects of butylated hydroxyanisole on hepatic in vivo DNA binding and in vitro biotransformation of aflatoxin Bi in the rat and mouse. Toxicol. Appl. Pharmacol. 90:401-9
36. 1. Carcinogenesis 6:1227-29
37. 1 to DNA in guinea pig tissue microsomes. Carcinogenesis 11:1915-19
38. 1 by lipoxygenases, prostaglandin-H synthase and cytochromeP450 monooxygenase in guinea-pig tissues. Carcinogenesis 13:533-39
39. Henke D, Danilowicz RM, Curtis JF, Boucher RC, Eling TE. 1988. Metabolism of arachidonic acid by human nasal and bronchial epithelial cells. Arch. Biochem. Biophys. 268:426-36
40. Kusner EJ, Marks RL, Aharony D, Krell RD. 1989. Inhibition by REV-5901 of leukotriene release from guinea pig and human lung tissue in vitro. Biochem. Pharmacol. 38:4183-89
41. Eaton DL, Monroe DH, Bellamy G, Kalman DA. 1988. Identification of a novel dihydroxy metabolite of aflatoxin Bi produced in vitro and in vivo in rats and mice. Chem. Res. Toxicol. 1:108-14
42. 1-induced cytotoxicity and inhibition of RNA synthesis in isolated rat hepatocytes. Biochem. Biophys. Res. Commun. 115:15-21
43. Decad GM, Dougherty KK, Hsieh DPH, Byard JL. 1979. Metabolism of aflatoxin Bi in cultured mouse hepatocytes: comparison with rat and effects of cyclohexene oxide and diethylmaleate. Toxicol. Appl. Pharmacol. 50:429-36
44. 1 metabolism. Biochemistry 28:7546-54
45. Neal GE, Colley PJ. 1978. Some high-performance liquid- Chromatographic studies of the metabolism of aflatoxins by rat liver microsomal preparations. Biochem. J. 174:839-51
46. 1 binding to exogenous and endogenous DNA by cytosolic glutathione S-transferases in rat and hamster livers. Carcinogenesis 5:269-76
47. 1 using the fertile chicken egg. Toxicol. Appl. Pharmacol. 23:528-31
48. 1 as evaluated with the chicken embryo and bacterial auxotrophs. Toxicol. Appl. Pharmacol. 30:237-42
49. Coulombe RA, Shelton DW, Sinnhuber RO, Nixon JE. 1982. Comparative mutagenicity of aflatoxins using a Salmonella/trout hepatic enzyme activation system. Carcinogenesis 3:1261-64
50. 1 in tracheal explants from Syrian hamster. Toxicology 32:117-30
51. 1 in the rat. Food Chem. Toxicol. 22:1027
52. 2. Tetrahedron Lett. 25:2799-2803
53. van Egmond HP. 1994. Aflatoxins in milk. See Ref. 1, pp. 365-82
54. 1 in rainbow trout (Salmo gairdneri) and its enhancement by cyclopropene fatty acids. J. Natl. Cancer lnst. 53:1285-88
55. 1 in rat liver. J. Natl. Cancer lnst. 47:585-92
56. 1 by human liver microsomes: role of cytochrome P450 IIIA enzymes. Toxicol. Appl. Pharmacol. 108:436-47
57. 1. Chem. Res. Toxicol. 5:202-10
58. 1 and synergistic effect of cyclopropenoid fatty acids. J. Natl. Cancer Inst. 64:523-27
59. 1 in the monkey, rat and mouse. Toxicol. Appl. Pharmacol. 55:115-25
60. 1 in human liver microsomes. Cancer Res. In press
61. 1 by human liver tissue from Thailand. Am. Assoc. Cancer Res. 34:162
62. 1 by several forms of purified cytochrome P-450. Mutat. Res. 174:-85-88
63. 1 by liver rat microsomes and isolated hepatocytes in vitro. Chem. Biol. Interact. 35:145-57
64. 1 hepatocarcinogenesis in the rat. Cancer Res. 47:5218-23
65. 3-450 gene. J. Biol. Chem. 263:12584-95
66. 1 and comparison to CYP1A2 and CYP2A3. Carcinogenesis 12:255-59